Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Helena Hohtari; Niels Pallisgaard; Matti Kankainen; Pekka Ellonen; Oscar Brück; Timo Siitonen; Marjaana Säily; Marjatta Sinisalo; Marja Pyörälä; Maija Itälä-Remes; Perttu Koskenvesa; Erkki Elonen; Satu Mustjoki; Kimmo Porkka

doi:10.3324/haematol.2021.280578

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Haematologica. 2022 Aug 1;107(8):1971-1976. doi: 10.3324/haematol.2021.280578.

Authors

Affiliations

¹ Hematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
² Department of Pathology, Zealand University Hospital, Roskilde.
³ Hematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Laboratory of Genetics, HUS Diagnostic Center, Hospital District of Helsinki and Uusimaa (HUS), Helsinki, Finland; Medical and Clinical Genetics, University of Helsinki, Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
⁴ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki.
⁵ Division of Hematology, Oulu University Hospital, Oulu.
⁶ Division of Hematology, Tampere University Hospital, Tampere.
⁷ Division of Hematology, Kuopio University Hospital, Kuopio.
⁸ Division of Hematology, Turku University Hospital, Turku.
⁹ Division of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
¹⁰ Hematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland; Department of Clinical Chemistry, University of Helsinki, Helsinki.
¹¹ Hematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland; Division of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.

No abstract available

MeSH terms

DNA Copy Number Variations
Humans
Philadelphia Chromosome*
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics

Grants and funding

Funding: This study was supported by the Doctoral Program in Clinical Research at the University of Helsinki and personal grants (to HH) from Emil Aaltonen Foundation, Ida Montin Foundation, Blood Disease Research Foundation, Finnish Hematology Association, Finnish Medical Foundation, Biomedicum Helsinki Foundation, Paulo Foundation, (to SM) Finnish Cancer Organizations, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Relander Foundation, and state funding for university-level health research in Finland. The laboratory analytics costs of this study were funded by Incyte.